Overdose of the HIV Medicine Genvoya® in Two Auto-Intoxications. Issue 1 (3rd August 2022)

• Record Type: Journal Article
• Authors: Gys, Celine; Mortelé, Olivier; van Rafelghem, Babette; Berry, Eleanor; van Nuijs, Alexander L N; Lambert, Willy; Jacobs, Werner; Schouwers, Sofie; Meskal, Anissa; Van Hemeldonck, Ellen; Heytens, Luc; Neels, Hugo; Covaci, Adrian
• Is Part Of: Journal of analytical toxicology. Volume 47:Issue 1(2023)
• Page Start: e1
• Page End: e5
• Publication Date: 2022-08-03
• Subjects: Drugs -- Analysis -- Periodicals; Drugs -- Toxicity testing -- Periodicals; 615.907
• DOI: 10.1093/jat/bkac056
• Languages: English
• ISSNs: 0146-4760

Abstract

Abstract: Toxicological data on overdose with human immunodeficiency virus inhibitors are scarce. We present a case report of two independent suicide attempts by self-administered overdose with the same antiretroviral medicine Genvoya ® (emtricitabine/elvitegravir/tenofovir alafenamide/cobicistat). Both patients were admitted to the hospital and presented with a loss of consciousness, lactic acidosis, elevated hepatic transaminase levels and hemodynamic instability. While one patient survived with advanced supportive measures, the other passed away. Emtricitabine levels were measured in vivo in various consecutive serum samples and postmortem urine, peripheral and cardiac serum samples and confirmed excessive use in both cases. This is the first time that emtricitabine levels following overdose are reported. Although measured concentrations for emtricitabine were quite similar in these cases, metabolic acidosis was more pronounced in the fatal case. The difference in outcomes between the two could be due to a difference in physiological status, susceptibility to accumulation and adverse effects, and perhaps a varying interval between ingestion and the start of supportive measures.